structural communications
Therapeutic target-site variability in α1-antitrypsin characterized at high resolution
aInstitute of Structural and Molecular Biology, Crystallography, Department of Biological Sciences, Birkbeck College, Malet Street, London WC1E 7HX, England, and bCambridge Institute for Medical Research, Department of Medicine, University of Cambridge, Hills Road, Cambridge CB2 0XY, England
*Correspondence e-mail: b.gooptu@mail.cryst.bbk.ac.uk
The intrinsic propensity of α1-antitrypsin to undergo conformational transitions from its metastable native state to hyperstable forms provides a motive force for its antiprotease function. However, aberrant conformational change can also occur via an intermolecular linkage that results in polymerization. This has both loss-of-function and gain-of-function effects that lead to deficiency of the protein in human circulation, emphysema and hepatic cirrhosis. One of the most promising therapeutic strategies being developed to treat this disease targets small molecules to an allosteric site in the α1-antitrypsin molecule. Partial filling of this site impedes polymerization without abolishing function. Drug development can be improved by optimizing data on the structure and dynamics of this site. A new 1.8 Å resolution structure of α1-antitrypsin demonstrates structural variability within this site, with associated fluctuations in its upper and lower entrance grooves and ligand-binding characteristics around the innermost stable enclosed hydrophobic recess. These data will allow a broader selection of chemotypes and derivatives to be tested in silico and in vitro when screening and developing compounds to modulate conformational change to block the pathological mechanism while preserving function.
Keywords: α1-antitrypsin; drug development.
PDB reference: α1-antitrypsin, 3ne4
1. Introduction
α1-Antitrypsin is the most abundant antiprotease in the human circulation (Heimburger & Haupt, 1965). It is also the archetypal member of the serpin (serine protease inhibitor) superfamily of proteins (Silverman et al., 2001). Serpins are characterized by a metastable native fold consisting of nine α-helices (A–I) and three β-pleated sheets (A–C). A propensity to undergo stabilizing conformational change involving expansion of β-sheet A is utilized in the structural transitions required for protease inhibition (Huntington et al., 2000). However, pathological point mutations trigger aberrant opening of β-sheet A, allowing serpins to homopolymerize via exchange of complementary stabilizing motifs between neighbouring molecules (Gooptu & Lomas, 2009). Polymerization of α1-antitrypsin results in emphysema and hepatic cirrhosis, as well as circulating deficiency, through gain-of-function and loss-of-function effects (Gooptu & Lomas, 2008).
Polymerization may be blocked directly by annealing reactive-loop analogue β-sheet A (Chang et al., 2011; Lomas et al., 1992). However, this approach also abolishes functional inhibitory activity and faces technical challenges in drug development. A promising alternative strategy blocks polymerization by targeting an allosteric site, a cavity flanking β-sheet A that is sealed during loop insertion (Parfrey et al., 2003; Gooptu et al., 2009; Fig. 1). Mutagenesis studies show that partial occupation of this site can impede polymerization and preserve the inhibitory function of α1-antitrypsin. Lead molecules targeted to fully occupy this site block polymerization but, as with s4A-binding abolish inhibitory function (Mallya et al., 2007). There is therefore a need to develop smaller molecules that mimic the effects of a space-filling mutation more faithfully. Reducing the size of screened moieties to the `fragment' range (<250 Da) may help identify promising initial hits, but at the expense of binding affinity and specificity. To develop hits into well targeted molecules will therefore require their modification, via derivatives that `grow' the molecule based upon what is known about the binding site. The process will be aided by as much high-resolution data and dynamic information as possible. We have now solved the highest resolution (1.8 Å) of α1-antitrypsin. The increased detail provides insight into the mechanism of β-sheet A expansion by delineating the hydration of a relatively hydrophobic environment around the highly conserved Trp194 residue, rendering the initial loop insertion site conformationally labile. These data nicely explain findings from previous tryptophan fluorescence studies of conformational change during polymerization. Moreover, comparison with 2.0 Å resolution structures characterizes variation in the conformational dynamics of the allosteric pocket in solution. This demonstrates that the allosteric site is likely to be one of the most variable environments around the α1-antitrypsin molecule and will aid future drug targeting to this feature.
to the central loop insertion site (s4A) in2. Methods
pQE31 plasmid containing cDNA encoding hexahistidine-tagged recombinant wild-type α1-antitrypsin was transfected into XL1 Blue Escherichia coli cells (Stratagene). The proteins were expressed and purified as described previously (Parfrey et al., 2003). They were characterized using SDS–PAGE, nondenaturing PAGE and transverse urea gradient (TUG) PAGE, circular-dichroism (CD) spectroscopy and enzyme-inhibitory activity and kinetics assays (Dafforn et al., 2004; Stone & Hofsteenge, 1986).
Crystals of α1-antitrypsin were grown in 0.1 M MMT buffer (1:2:2 DL-malic acid:MES:Tris base) pH 6.0, 20%(w/v) PEG 1500, 330 µM N-{4-hydroxy-3-methyl-5-[(1H-1,2,4,5-tetrazol-3-yl)sulfanyl]phenyl}-4-methylbenzenesulfonamide by hanging-drop vapour diffusion at 293 K. These crystals were then loop-mounted and cryocooled in cryoprotectant buffer [0.1 M MMT pH 6.0, 20%(w/v) PEG 1500, 20%(v/v) glycerol]. Synchrotron diffraction data were collected on beamline 23.1 at the ESRF, Grenoble, France. Processing of the X-ray diffraction data was performed using iMOSFLM (Battye et al., 2011) and SCALA (Evans, 2006). The structure of α1-antitrypsin was solved by with Phaser (McCoy et al., 2007) to a resolution of 1.8 Å using the coordinates of the native α1-antitrypsin (PDB entry 1qlp; Elliott et al., 2000) as a search model. An initial model was constructed using Coot (Emsley & Cowtan, 2004) and the structure was refined using REFMAC5 (Murshudov et al., 2011). Iterative cycles of model building and were carried out until the R factors stabilized. The stereochemistry of the final model (PDB entry 3ne4) was checked using PROCHECK (Laskowski et al., 1993).
The cavity flanking β-sheet A in the new structure was assessed and compared with those observed in the two structures of nearest resolution (PDB entries 1qlp and 2qug; Pearce et al., 2008) using the program SiteMap 2.5 and other programs from the Schrödinger suite (Schrödinger LLP, New York, USA). The crystal structures were prepared using the Protein Preparation Wizard protocol in the Maestro program. Ligands, waters and other cocrystallized agents were deleted and H atoms were added. The protassign script was used to optimize intramolecular contacts. The impref script was used to perform restrained minimization of the protein (default settings in Maestro v.9.2). All structures were superposed using the structalign utility from Schrödinger. A site was defined as an enclosed region comprising at least 15 site points (default settings in SiteMap v.2.5). SiteMap uses an algorithm to identify and characterize favourable sites in a protein structure for drug binding. Probe-based and energy-based methods are used to estimate the interaction energy between probe and protein along a three-dimensional grid that samples the space around the structural model. These values are combined with geometry terms to give a druggability scoring function that is a function of volume and site enclosure (solvent exclusion). A penalty factor is calculated for hydrophilicity. Other parameters that are calculated for each site are volume, solvent exposure, contacts, hydrophobicity and hydrogen-donor/acceptor sites.
3. Results and discussion
We have determined the highest resolution (1.8 Å) crystallographic structure of native α1-antitrypsin solved to date (PDB entry 3ne4; Fig. 2a). are listed in Table 1. As expected, its overall fold and the positioning of secondary-structure elements are highly similar to the previous 2.0 Å resolution structure (Elliott et al., 2000; PDB entry 1qlp; Cα r.m.s.d. 0.3 Å; Fig. 2b). However, the higher resolution is associated with a reduction in B factors overall (Fig. 2c) and improves confidence in details such as the positioning of side-chain atoms and water molecules.
‡Rcryst = . §Rfree = Rcryst for 5% of reflections omitted from ¶Bave values are average temperature factors for all molecules in the |
Occupancy of alternative rotameric orientations for Val216 and Ile340 became apparent during β-strand s4C and in the hinge region between β-strand s5A and the reactive loop. Coordination of the canonical inhibitory conformation at the reactive centre of the molecule by a water molecule between the side chain of Ser283 and the main-chain carbonyls of the P2 and P1′ residues is confirmed in the new structure (Fig. 2a, box I). This water is observed in only one (PDB entry 1qlp) of the 2.0 Å resolution crystal structures of native α1-antitrypsin solved previously. In the other case (PDB entry 2qug; Pearce et al., 2008), similarly to the 2.1 Å resolution structure (PDB entry 1hp7; Kim et al., 2001), this water is not seen and the canonical conformation of these residues is distorted. Accordingly, the r.m.s.d. is greater for 3ne4 and 2qug across the reactive-loop residues (340–362) than between 3ne4 and 1qlp (Fig. 2b). Moreover, the solvation environment between Trp194 and the plane of β-sheet A is clearly seen to involve three water molecules (numbered 7, 49 and 54) whose centroids lie within 3–5 Å of the Trp side chain (Fig. 2a, box II). They are coordinated by nearby main-chain carbonyl O atoms. This is of interest since changes around Trp194 are reported by changes in intrinsic fluorescence spectrometry of α1-antitrypsin. It is therefore commonly used as a reporter residue for conformational change involving rearrangements around its position underlying the top of β-sheet A (Dafforn et al., 1999; Tew & Bottomley, 2001). High-resolution structures of latent (Im et al., 2002) and cleaved (Yamasaki et al., 2010) α1-antitrypsin clearly show the exclusion of solvent in this region. Previous structures of native wild-type α1-antitrypsin (Elliott et al., 2000; Pearce et al., 2008) have indicated the presence of zero, one or two waters in this region. In 3ne4 one of the three water molecules hydrogen bonds to the carbonyl O atom of Thr339. This interaction prevents the formation of a typical interstrand hydrogen bond between the carbonyl of residue Thr339 at the top of s5A and Gly192 at the top of s3A. It therefore facilitates the opening of the upper s4A insertion site, which necessitates separation of these residues at the top of s3A and s5A. The upper s4A site superficially appears to be less accessible to reactive-loop or peptide annealing in α1-antitrypsin compared with other native serpins. However, this finding shows how initial insertion of a residue in this `P14 position' (Schechter and Berger notation; Schechter & Berger, 1967) does not come at the cost of breaking an interstrand hydrogen bond in α1-antitrypsin.
These are found onFascinatingly, the intrinsic fluorescence spectrum of α1-antitrypsin reports the formation of both the intermediate and polymer during polymerization by a small blue shift and increased intensity attributable to Trp194 (Dafforn et al., 1999). This is consistent with increased solvent exclusion, since increased solvent exposure of this residue is reported instead by a large and no change in maximal intensity (Tew & Bottomley, 2001). If formation of the monomeric intermediate were associated with simple opening of the upper s4A site, exposing Trp194 to a bulk-solvent environment, it should predictably be reported by a and unchanged intensity. This would presumably apply even more if the intermediate were substantially unfolded, as recently proposed (Yamasaki et al., 2008). However, these findings may be explained if intermediate formation is instead associated with a decrease in the local solvation of Trp194, e.g. by filling of the upper s4A site to exclude the three water molecules, as previously modelled (Gooptu et al., 2000, 2009). Thus, changes in this solvation state are likely to be intimately connected with conformational change in α1-antitrypsin, consistent with the sensitivity of Trp194 as a reporter moiety.
3.1. Conformational variability in the cavity flanking β-sheet A
The most significant difference in main-chain conformation between the new structure and the search model 1qlp occurs at the hD–s2A turn (residues 105–110, Fig. 2b) that forms the upper boundary of the hydrophobic pocket targeted for allosteric polymerization blockade (Fig. 1; Mallya et al., 2007). This region is typically less well ordered than the overall fold in crystal structures of many native serpins, including α1-antitrypsin. The improved resolution obtained in the current study aided confident fitting into observed density through use of an OMIT map (Fig. 2a, box III).
The hD–s2A region is associated with relatively low B factors in latent (Im et al., 2002) and cleaved (Yamasaki et al., 2010) species in which the cavity is filled, but high B factors relative to other regions in crystal structures of native α1-antitrypsin. Despite this and the differences observed here between the 1qlp and 3ne4 structures, they are both based upon data to high resolution and have good enough bond geometries to be reasonably confident of the accuracy of model building in each case. Moreover, the turn is not near lattice contacts in either structure. The differences between 1qlp and 3ne4 are therefore likely to reflect alternative conformations of this region that are involved in conformational exchange.
We examined variability in the allosteric cavity flanking β-sheet A by SiteMap analysis of high-resolution structures: 1qlp (which was first used to define it; Elliott et al., 2000), 2qug (Pearce et al., 2008), another 2.0 Å resolution of native α1-antitrypsin, and 3ne4 (Fig. 3). In addition to the variability in the hD–s2A turn region, the major differences observed between the cavity in 1qlp and 3ne4 are the topology at its upper and lower poles and, where topology is conserved, in the hydrogen-bond acceptor characteristics (Fig. 3, red). The hD–s2A turn movement observed in 3ne4 relative to 1qlp abolishes an upper recess within the cavity in the latter structure (top left panel, green ellipse). In contrast, in 3ne4 a groove at the lower pole of the cavity entrance becomes continuous with it (top right panel, green ellipse). An innermost hydrophobic (Fig. 3, yellow) chamber shows similar topology between 1qlp and 3ne4, as do the hydrogen-bond donor (blue) characteristics in the conserved core region.
The hD–s2A turn in 2qug more closely resembles that seen in 3ne4 than the same region in 1qlp (Fig. 2b). However, this feature alone does not appear to entirely dictate the overall cavity characteristics assessed by SiteMap. Thus, while the allosteric cavity in 2qug displays a truncated upper channel relative to 1qlp, it does not become continuous with a channel at its lower pole. Moreover, the central region of the hydrophobic chamber seen in the other structures is lost in 2qug, dividing it. 2qug maintains similar hydrogen-bond acceptor characteristics of those cavity regions that are shared with the other two structures. However, the hydrogen-bond donor characteristics in the 2qug cavity are more concentrated within a narrower distribution than that in either 1qlp or 3ne4. SiteMap also scores sites for a number of parameters that have been correlated with tight ligand binding and druggability (i.e. tight binding of drug-like molecules; Halgren, 2009). These outputs are listed for the cavities assessed in the three different structures, together with cutoffs and mean values correlated with observed behaviour (Table 2). The overall scores for ligand-binding propensities (SiteScore) and drug-like molecule-binding propensities (Dscore) are also listed. These data are consistent with the topological observations in Fig. 3 in quantifying variability around favourable characteristics for drug binding.
|
Taken together, these findings characterize the cavity flanking β-sheet A as a highly dynamic feature in native α1-antitrypsin. They indicate that the most stable features are the two hydrophobic regions that remain in 2qug and the hydrogen-bond donor/acceptor features immediately contiguous to them. The uppermost of these regions closely corresponds to the minimal pharmacophore target region identified by analysis of the 2.2 Å resolution structure of Thr114Phe α1-antitrypsin (Gooptu et al., 2009). Initial fragment or small-molecule screens targeting this cavity may therefore most efficiently be directed against these regions. Compounds binding well here could serve as templates for a diverse range of derivatives. Different elaborating motifs within the derivative libraries could then test the alternative hydrogen-bonding environments and communicating channel topologies identified by our structural comparison.
The use of relatively low-resolution crystal structures as a supplement to high-resolution structures has been proposed as a promising strategy for sampling conformational space explored by drug targets and thus aiding drug design (Furnham et al., 2006). In the case of the cavity flanking β-sheet A, comparison between the 1qlp, 2qug and 3ne4 structures of α1-antitrypsin provides the benefit of this outcome without the potential inaccuracies of model building inherent at lower resolutions.
Acknowledgements
We thank Dr Claire Naylor for her technical assistance with this work. AOMP was supported by a Wellcome Trust PhD studentship, LS was supported by an MRC PhD studentship administered by Birkbeck College, MPN was supported by a Wellcome Trust VIP Fellowship and BG was supported by a Wellcome Trust Intermediate Clinical Fellowship.
References
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. W. (2011). Acta Cryst. D67, 271–281. Web of Science CrossRef CAS IUCr Journals Google Scholar
Chang, Y.-P., Mahadeva, R., Patschull, A. O. M., Nobeli, I., Ekeowa, U. I., McKay, A. R., Thalassinos, K., Irving, J. A., Haq, I., Nyon, M. P., Christodoulou, J., Ordóñez, A., Miranda, E. & Gooptu, B. (2011). In the press. Google Scholar
Dafforn, T. R., Mahadeva, R., Elliott, P. R., Sivasothy, P. & Lomas, D. A. (1999). J. Biol. Chem. 274, 9548–9555. Web of Science CrossRef PubMed CAS Google Scholar
Dafforn, T. R., Pike, R. N. & Bottomley, S. P. (2004). Methods, 32, 150–158. Web of Science CrossRef PubMed CAS Google Scholar
DeLano, W. L. (2002). PyMOL. https://www.pymol.org. Google Scholar
Elliott, P. R., Pei, X. Y., Dafforn, T. R. & Lomas, D. A. (2000). Protein Sci. 9, 1274–1281. CrossRef PubMed CAS Google Scholar
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Evans, P. (2006). Acta Cryst. D62, 72–82. Web of Science CrossRef CAS IUCr Journals Google Scholar
Furnham, N., Blundell, T. L., DePristo, M. A. & Terwilliger, T. C. (2006). Nature Struct. Mol. Biol. 13, 184–185. Web of Science CrossRef CAS Google Scholar
Gooptu, B., Hazes, B., Chang, W.-S. W., Dafforn, T. R., Carrell, R. W., Read, R. J. & Lomas, D. A. (2000). Proc. Natl Acad. Sci. USA, 97, 67–72. Web of Science CrossRef PubMed CAS Google Scholar
Gooptu, B. & Lomas, D. A. (2008). J. Exp. Med. 205, 1529–1534. Web of Science CrossRef PubMed CAS Google Scholar
Gooptu, B. & Lomas, D. A. (2009). Annu. Rev. Biochem. 78, 147–176. Web of Science CrossRef PubMed CAS Google Scholar
Gooptu, B., Miranda, E., Nobeli, I., Mallya, M., Purkiss, A., Brown, S. C., Summers, C., Phillips, R. L., Lomas, D. A. & Barrett, T. E. (2009). J. Mol. Biol. 387, 857–868. Web of Science CrossRef PubMed CAS Google Scholar
Halgren, T. A. (2009). J. Chem. Inf. Model. 49, 377–389. Web of Science CrossRef PubMed CAS Google Scholar
Heimburger, N. & Haupt, H. (1965). Clin. Chim. Acta, 12, 116–118. CrossRef CAS PubMed Web of Science Google Scholar
Huntington, J. A., Read, R. J. & Carrell, R. W. (2000). Nature (London), 407, 923–926. Web of Science CrossRef PubMed CAS Google Scholar
Im, H., Woo, M.-S., Hwang, K. Y. & Yu, M.-H. (2002). J. Biol. Chem. 277, 46347–46354. Web of Science CrossRef PubMed CAS Google Scholar
Kim, S.-J., Woo, J.-R., Seo, E. J., Yu, M.-H. & Ryu, S.-E. (2001). J. Mol. Biol. 306, 109–119. Web of Science CrossRef PubMed CAS Google Scholar
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J. Appl. Cryst. 26, 283–291. CrossRef CAS Web of Science IUCr Journals Google Scholar
Lomas, D. A., Evans, D. L., Finch, J. T. & Carrell, R. W. (1992). Nature (London), 357, 605–607. CrossRef PubMed CAS Web of Science Google Scholar
Mallya, M., Phillips, R. L., Saldanha, S. A., Gooptu, B., Brown, S. C., Termine, D. J., Shirvani, A. M., Wu, Y., Sifers, R. N., Abagyan, R. & Lomas, D. A. (2007). J. Med. Chem. 50, 5357–5363. Web of Science CrossRef PubMed CAS Google Scholar
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. Web of Science CrossRef CAS IUCr Journals Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Parfrey, H., Mahadeva, R., Ravenhill, N. A., Zhou, A., Dafforn, T. R., Foreman, R. C. & Lomas, D. A. (2003). J. Biol. Chem. 278, 33060–33066. Web of Science CrossRef PubMed CAS Google Scholar
Pearce, M. C., Morton, C. J., Feil, S. C., Hansen, G., Adams, J. J., Parker, M. W. & Bottomley, S. P. (2008). Protein Sci. 17, 2127–2133. Web of Science CrossRef PubMed CAS Google Scholar
Schechter, I. & Berger, A. (1967). Biochem. Biophys. Res. Commun. 27, 157–162. CrossRef CAS PubMed Web of Science Google Scholar
Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C., Coughlin, P. B., Gettins, P. G., Irving, J. A., Lomas, D. A., Luke, C. J., Moyer, R. W., Pemberton, P. A., Remold-O'Donnell, E., Salvesen, G. S., Travis, J. & Whisstock, J. C. (2001). J. Biol. Chem. 276, 33293–33296. Web of Science CrossRef PubMed CAS Google Scholar
Stone, S. R. & Hofsteenge, J. (1986). Biochemistry, 25, 4622–4628. CrossRef CAS PubMed Web of Science Google Scholar
Tew, D. J. & Bottomley, S. P. (2001). J. Mol. Biol. 313, 1161–1169. Web of Science CrossRef PubMed CAS Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Yamasaki, M., Li, W., Johnson, D. J. & Huntington, J. A. (2008). Nature (London), 455, 1255–1258. Web of Science CrossRef PubMed CAS Google Scholar
Yamasaki, M., Sendall, T. J., Harris, L. E., Lewis, G. M. & Huntington, J. A. (2010). J. Biol. Chem. 285, 30752–30758. Web of Science CrossRef CAS PubMed Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.